TY - JOUR A1 - Breun, Maria A1 - Monoranu, Camelia M. A1 - Kessler, Almuth F. A1 - Matthies, Cordula A1 - Löhr, Mario A1 - Hagemann, Carsten A1 - Schirbel, Andreas A1 - Rowe, Steven P. A1 - Pomper, Martin G. A1 - Buck, Andreas K. A1 - Wester, Hans-Jürgen A1 - Ernestus, Ralf-Ingo A1 - Lapa, Constantin T1 - [\(^{68}\)Ga]-Pentixafor PET/CT for CXCR4-mediated imaging of vestibular schwannomas JF - Frontiers in Oncology N2 - We have recently demonstrated CXCR4 overexpression in vestibular schwannomas (VS). This study investigated the feasibility of CXCR4-directed positron emission tomography/computed tomography (PET/CT) imaging of VS using the radiolabeled chemokine ligand [\(^{68}\)Ga]Pentixafor. Methods: 4 patients with 6 primarily diagnosed or pre-treated/observed VS were enrolled. All subjects underwent [\(^{68}\)Ga]Pentixafor PET/CT prior to surgical resection. Images were analyzed visually and semi-quantitatively for CXCR4 expression including calculation of tumor-to-background ratios (TBR). Immunohistochemistry served as standard of reference in three patients. Results: [\(^{68}\)Ga]Pentixafor PET/CT was visually positive in all cases. SUV\(_{mean}\) and SUV\(_{max}\) were 3.0 ± 0.3 and 3.8 ± 0.4 and TBR\(_{mean}\) and TBR\(_{max}\) were 4.0 ± 1.4 and 5.0 ± 1.7, respectively. Histological analysis confirmed CXCR4 expression in tumors. Conclusion: Non-invasive imaging of CXCR4 expression using [\(^{68}\)Ga]Pentixafor PET/CT of VS is feasible and could prove useful for in vivo assessment of CXCR4 expression. KW - vestibular schwannoma KW - CXCR4 KW - PET/CT KW - molecular imaging KW - Pentixafor Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-201863 VL - 9 IS - 503 ER - TY - JOUR A1 - Kirscher, Lorenz A1 - Deán-Ben, Xosé Luis A1 - Scadeng, Miriam A1 - Zaremba, Angelika A1 - Zhang, Qian A1 - Kober, Christina A1 - Fehm, Thomas Felix A1 - Razansky, Daniel A1 - Ntziachristos, Vasilis A1 - Stritzker, Jochen A1 - Szalay, Aladar A. T1 - Doxycycline Inducible Melanogenic Vaccinia Virus as Theranostic Anti-Cancer Agent JF - Theranostics N2 - We reported earlier the diagnostic potential of a melanogenic vaccinia virus based system in magnetic resonance (MRI) and optoacoustic deep tissue imaging (MSOT). Since melanin overproduction lead to attenuated virus replication, we constructed a novel recombinant vaccinia virus strain (rVACV), GLV-1h462, which expressed the key enzyme of melanogenesis (tyrosinase) under the control of an inducible promoter-system. In this study melanin production was detected after exogenous addition of doxycycline in two different tumor xenograft mouse models. Furthermore, it was confirmed that this novel vaccinia virus strain still facilitated signal enhancement as detected by MRI and optoacoustic tomography. At the same time we demonstrated an enhanced oncolytic potential compared to the constitutively melanin synthesizing rVACV system. KW - reporter gene KW - oncolysis KW - molecular imaging KW - virotherapy Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-124987 VL - 5 IS - 10 ER - TY - JOUR A1 - Lambertini, Alessandro A1 - Hartrampf, Philipp E. A1 - Higuchi, Takahiro A1 - Serfling, Sebastian E. A1 - Meybohm, Patrick A1 - Schirbel, Andreas A1 - Buck, Andreas K. A1 - Werner, Rudolf A. T1 - CXCR4-targeted molecular imaging after severe SARS-Cov-2 infection JF - European Journal of Nuclear Medicine and Molecular Imaging N2 - No abstract available. KW - CXCR4-targeting KW - SARS-CoV-2 KW - COVID-19 KW - molecular imaging Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-324619 VL - 50 IS - 1 ER - TY - JOUR A1 - Lapa, Constantin A1 - Schreder, Martin A1 - Schirbel, Andreas A1 - Samnick, Samuel A1 - Kortüm, Klaus Martin A1 - Herrmann, Ken A1 - Kropf, Saskia A1 - Einsele, Herrmann A1 - Buck, Andreas K. A1 - Wester, Hans-Jürgen A1 - Knop, Stefan A1 - Lückerath, Katharina T1 - [\(^{68}\)Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - comparison to [\(^{18}\)F]FDG and laboratory values JF - Theranostics N2 - Chemokine (C-X-C motif) receptor 4 (CXCR4) is a key factor for tumor growth and metastasis in several types of human cancer including multiple myeloma (MM). Proof-of-concept of CXCR4-directed radionuclide therapy in MM has recently been reported. This study assessed the diagnostic performance of the CXCR4-directed radiotracer [\(^{68}\)Ga]Pentixafor in MM and a potential role for stratifying patients to CXCR4-directed therapies. Thirty-five patients with MM underwent [\(^{68}\)Ga]Pentixafor-PET/CT for evaluation of eligibility for endoradiotherapy. In 19/35 cases, [\(^{18}\)F]FDG-PET/CT for correlation was available. Scans were compared on a patient and on a lesion basis. Tracer uptake was correlated with standard clinical parameters of disease activity. [\(^{68}\)Ga]Pentixafor-PET detected CXCR4-positive disease in 23/35 subjects (66%). CXCR4-positivity at PET was independent from myeloma subtypes, cytogenetics or any serological parameters and turned out as a negative prognostic factor. In the 19 patients in whom a comparison to [\(^{18}\)F]FDG was available, [\(^{68}\)Ga]Pentixafor-PET detected more lesions in 4/19 (21%) subjects, [\(^{18}\)F]FDG proved superior in 7/19 (37%). In the remaining 8/19 (42%) patients, both tracers detected an equal number of lesions. [\(^{18}\)F]FDG-PET positivity correlated with [\(^{68}\)Ga]Pentixafor-PET positivity (p=0.018). [\(^{68}\)Ga]Pentixafor-PET provides further evidence that CXCR4 expression frequently occurs in advanced multiple myeloma, representing a negative prognostic factor and a potential target for myeloma specific treatment. However, selecting patients for CXCR4 directed therapies and prognostic stratification seem to be more relevant clinical applications for this novel imaging modality, rather than diagnostic imaging of myeloma. KW - medicine KW - multiple myeloma KW - FDG KW - molecular imaging KW - CXCR4 KW - PET KW - radionuclide therapy KW - theranostics Y1 - 2017 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-172106 VL - 7 IS - 1 ER - TY - JOUR A1 - Lückerath, Katharina A1 - Lapa, Constantin A1 - Albert, Christa A1 - Herrmann, Ken A1 - Jörg, Gerhard A1 - Samnick, Samuel A1 - Einsele, Herrmann A1 - Knop, Stefan A1 - Buck, Andreas K. T1 - \(^{11}\)C-Methionine-PET: a novel and sensitive tool for monitoring of early response to treatment in multiple myeloma JF - Oncotarget N2 - Multiple myeloma (MM) remains an essentially incurable hematologic malignancy. However, new treatment modalities and novel drugs have been introduced and thus additional tools for therapy monitoring are increasingly needed. Therefore, we evaluated the radiotracers \(^{11}\)C-Methionine (paraprotein-biosynthesis) and \(^{18}\)F-FDG (glucose-utilization) for monitoring response to anti-myeloma-therapy and outcome prediction. Influence of proteasome-inhibition on radiotracer-uptake of different MM cell-lines and patient-derived CD138\(^{+}\) plasma cells was analyzed and related to tumor-biology. Mice xenotransplanted with MM. 1S tumors underwent MET- and FDG-\(\mu\)PET. Tumor-to-background ratios before and after 24 h, 8 and 15 days treatment with bortezomib were correlated to survival. Treatment reduced both MET and FDG uptake; changes in tracer-retention correlated with a switch from high to low CD138-expression. In xenotransplanted mice, MET-uptake significantly decreased by 30-79% as early as 24 h after bortezomib injection. No significant differences were detected thus early with FDG. This finding was confirmed in patient-derived MM cells. Importantly, early reduction of MET-but not FDG-uptake correlated with improved survival and reduced tumor burden in mice. Our results suggest that MET is superior to FDG in very early assessment of response to anti-myeloma-therapy. Early changes in MET-uptake have predictive potential regarding response and survival. MET-PET holds promise to individualize therapies in MM in future. KW - positron emission tomography KW - imaging techniques KW - experience KW - \(^{11}\)C-Methionine-PET KW - treatment response KW - molecular imaging KW - multiple myeloma KW - management KW - \(^{18}\)F-FDG PET/CT KW - bone disease KW - stem-cell transplantation KW - esophagogastric junction Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-148688 VL - 6 IS - 10 ER - TY - JOUR A1 - Lückerath, Katharina A1 - Lapa, Constantin A1 - Malzahn, Uwe A1 - Samnick, Samuel A1 - Einsele, Herrmann A1 - Buck, Andreas K. A1 - Herrmann, Ken A1 - Knop, Stefan T1 - 18FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation N2 - The aim of this study was to investigate the prognostic value of 18F-fluoro-deoxyglucose positron emission tomography–computed tomography (18F-FDG-PET/CT) in 37 patients with a history of multiple myeloma (MM) and suspected or confirmed recurrence after stem cell transplantation (SCT). All patients had been heavily pre-treated. Time to progression (TTP) and overall survival (OS) were correlated to a number of different PET-derived as well as clinical parameters. Impact on patient management was assessed. Absence of FDG-avid MM foci was a positive prognostic factor for both TTP and OS (p<0.01). Presence of >10 focal lesions correlated with both TTP (p<0.01) and OS (p<0.05). Interestingly, presence of >10 lesions in the appendicular skeleton proved to have the strongest association with disease progression. Intensity of glucose uptake and presence of extramedullary disease were associated with shorter TTP (p=0.037 and p=0.049, respectively). Manifestations in soft tissue structures turned out to be a strong negative predictor for both, TTP and OS (p<0.01, respectively). PET resulted in a change of management in 30% of patients. Our data underline the prognostic value of 18F-FDG-PET/CT in MM patients also in the setting of post-SCT relapse. PET/CT has a significant impact on patient management. KW - 18FDG-PET/CT KW - Multiple myeloma KW - molecular imaging KW - FDG-PET/CT Y1 - 2014 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-113107 ER - TY - JOUR A1 - Toyama, Yoshitaka A1 - Werner, Rudolf A. A1 - Ruiz-Bedoya, Camilo A. A1 - Ordonez, Alvaro A. A1 - Takase, Kei A1 - Lapa, Constantin A1 - Jain, Sanjay K. A1 - Pomper, Martin G. A1 - Rowe, Steven P. A1 - Higuchi, Takahiro T1 - Current and future perspectives on functional molecular imaging in nephro-urology: theranostics on the horizon JF - Theranostics N2 - In recent years, a paradigm shift from single-photon-emitting radionuclide radiotracers toward positron-emission tomography (PET) radiotracers has occurred in nuclear oncology. Although PET-based molecular imaging of the kidneys is still in its infancy, such a trend has emerged in the field of functional renal radionuclide imaging. Potentially allowing for precise and thorough evaluation of renal radiotracer urodynamics, PET radionuclide imaging has numerous advantages including precise anatomical co-registration with CT images and dynamic three-dimensional imaging capability. In addition, relative to scintigraphic approaches, PET can allow for significantly reduced scan time enabling high-throughput in a busy PET practice and further reduces radiation exposure, which may have a clinical impact in pediatric populations. In recent years, multiple renal PET radiotracers labeled with C-11, Ga-68, and F-18 have been utilized in clinical studies. Beyond providing a precise non-invasive read-out of renal function, such radiotracers may also be used to assess renal inflammation. This manuscript will provide an overview of renal molecular PET imaging and will highlight the transformation of conventional scintigraphy of the kidneys toward novel, high-resolution PET imaging for assessing renal function. In addition, future applications will be introduced, e.g. by transferring the concept of molecular image-guided diagnostics and therapy (theranostics) to the field of nephrology. KW - glomerular filtration rate KW - renal KW - kidney KW - renal function KW - positron emission tomography KW - nephrology KW - urology KW - molecular imaging KW - theranostics Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-260090 VL - 11 IS - 12 ER - TY - THES A1 - Vogel, Patrick T1 - Traveling Wave Magnetic Particle Imaging T1 - Traveling Wave Magnetic Particle Imaging N2 - Magnetic Particle Imaging (MPI) ist eine noch sehr junge Technologie unter den nicht-invasiven tomographischen Verfahren. Seit der ersten Veröffentlichung 2005 wurden einige Scannertypen und Konzepte vorgestellt, welche durch die Messung des Antwortsignals von superparamagnetischen Eisennanopartikeln (SPIOs) auf wechselnde Magnetfelder ein dreidi-mensionales Bild ihrer Verteilung berechnen können. Durch die direkte Messung des Tracers handelt es sich beim MPI um eine sehr sensitive und hochspezifische bildgebende Methode. Zu Beginn dieser Forschungsarbeit gab es nur wenige bekannte MPI-Scanner, die jedoch alle ein nur kleines Field-of-View (FOV) vorweisen konnten. Der Grund dafür liegt in der Ver-wendung von Permanentmagneten. Das Ziel war es nun, ein neues Konzept auszuarbeiten und einen 3D-MPI-Scanner zu entwer-fen, der in der Lage ist, ein mausgroßes Objekt zu messen. In dieser Arbeit wird ein alternatives Scannerkonzept für die dreidimensionale Bildge-bung superparamagnetischer Eisennanopartikel vorgestellt. Der Traveling Wave MPI-Scanner (TWMPI) basiert auf einem neu entwickelten Hauptspulensystem, welches aus mehreren Elektromagneten besteht. Dadurch ist die Hardware bereits in der Lage, eine Linie entlang der Symmetrieachse über einen großen Bereich dynamisch zu kodieren. Mit Hilfe weiterer Ab-lenkspulen kann schließlich ein FOV von 65 x 25 x 25 Millimetern dreidimensional abgetastet werden. Dazu stehen mehrere Scanverfahren zur Verfügung, welche das Probenvolumen li-nienweise oder ebenenweise abtasten und mit einer Auflösung von ca. 2 Millimetern die Ver-teilung der SPIOs in wenigen Millisekunden abbilden können. Mit diesem neuen Hardwareansatz konnte erstmals ein MPI-Scanner mit einem MR-Tomographen (MRT) kombiniert werden. Das MPI/MRT-Hybridsystem liefert tomographi-sche Bilder des Gewebes (MRT) und zeigt die Verteilung des eisenhaltigen Kontrastmittels (MPI), ohne die Probe bewegen zu müssen. In einer in-vivo Echtzeitmessung konnte der TWMPI-Scanner mit 20 Bildern pro Se-kunde die dynamische Verteilung eines eisenhaltigen Kontrastmittels im Körper und speziell im schlagenden Herzen eines Tieres darstellen. Diese Echtzeitfähigkeit eröffnet in der kardi-ovaskuläre Bildgebung neue Möglichkeiten. Erste Messungen mit funktionalisierten Eisenpartikeln zeigen die spezifische Bildge-bung verschiedener Zelltypen und stellen einen interessanten Aspekt für die molekulare Bild-gebung dar. Die Sensitivität des Scanners liegt dabei im Bereich von wenigen Mikrogramm Eisen pro Milliliter, was für den Nachweis von wenigen 10.000 mit Eisen markierten Zellen ausreicht. Neben Messungen an diversen Ferrofluiden und eisenhaltigen Kontrastmitteln konnte der Einfluss von massiven Materialen, wie Eisenstückchen oder Eisenspänen, auf die rekon-struierten Bilder untersucht werden. Erste Messungen an Gestein zeigen die Verteilung von Eiseneinschlüssen und bieten die Möglichkeit einer weiteren zerstörungsfreien Untersuchungsmethode für Materialwissen-schaftler und Geologen. Weiterführende Testmessungen mit einer unabhängigen μMPI-Anlage zeigen erste Ergebnisse mit Auflösungen im Mikrometerbereich und liefern Erkennt-nisse für den Umgang und Messung mit starken Gradientenfeldern. Eine Modifizierung der Messanlage erlaubt es, in gerade einmal 500 μs ein komplettes Bild aufzunehmen, womit die Bewegung eines Ferrofluidtropfens in Wasser sichtbar gemacht werden konnte. Damit ist diese TWMPI-Anlage das schnellste MPI-System und eröffnet die Möglichkeit grundlegende Erfahrungen in der Partikeldynamik zu erlangen. Der vorgestellte Traveling Wave MPI-Scanner ist ein alternativer Scannertyp, welcher sich von anderen MPI-Scannern abhebt. Mit neuen Ansätzen ist in der Lage ein mausgroßes Objekt auf dynamische Weise sehr schnell abzutasten. Dabei konnten in verschiedenen Mes-sungen die Funktionalität und Leistungsfähigkeit des TWMPI-Konzeptes demonstriert wer-den, welche die gesteckten Ziele deutlich übertreffen. N2 - Magnetic particle imaging (MPI) is still a very young technology among the non-invasive tomographic modalities. Since its first publication in 2005, several types of scanners and concepts were presented, which can reconstruct a three-dimensional image of the distri-bution of superparamagnetic iron-oxide nanoparticles (SPIOs) by measuring their magnetiza-tion response to varying magnetic fields. Due to the direct measurement of the tracer MPI is a very sensitive and highly specific imaging modality. At the beginning of this project only a few MPI-scanners were known, but all of them are limited to a small field-of-view (FOV). The reason for this is the use of permanent mag-nets. The aim of this work was to develop a new concept and design for a 3D-MPI-scanner, which is able to measure a mouse sized object. In this thesis an alternative scanner concept for three-dimensional imaging of super-paramagnetic iron nanoparticles is presented. The Traveling Wave-MPI-scanner (TWMPI) is based on a newly developed main coil system, which consists of a series of electromagnets. This coil array is by itself able to dynamically encode a line along the symmetry axis over an extended length. With additional offset coils the system is able to scan a FOV of 65 x 25 x 25 millimeters in three dimensions. For scanning the whole volume several tech-niques are available, which map the data line-by-line or slice-by-slice in a few milliseconds and yield the distribution of SPIOs with a resolution of about 2 millimeters. Using this new hardware approach a MPI-scanner was successfully combined with an MRI-scanner for the first time. The MPI/MRI-hybrid-system provides tomographic images of the tissue (MRI) and detects the distribution of iron-containing contrast agent (MPI), without the need to move the sample. In an in-vivo real-time measurement using the TWMPI-scanner the dynamic distribu-tion of an iron-containing contrast agent was visualized in the body and especially in the beat-ing heart of an animal with a temporal resolution of 20 frames per second. This real-time ca-pability opens up new possibilities in cardio-vascular imaging. First measurements using functionalized iron-oxide nanoparticles specifically detect different cell types and thereby provide an interesting aspect for molecular imaging. The sensi-tivity of the scanner is in the range of a few micrograms of iron per milliliter, which is suffi-cient to detect about 50,000 iron-labeled cells. In several studies the influence of various ferrofluids, iron-containing contrast agents and solid materials, such as pieces of iron or iron filings, were examined on the reconstructed images. First measurements on ferrous rock show the location of iron-inclusions and offer an-other non-destructive imaging technique for material scientists and geologists. Additional tests with an independent μMPI-system were performed to explore resolutions in the micrometer range and provide insights for handling and measuring with a high gradient strength. A modification of the setup allows to acquire a full slice in just 500 microseconds, which enable the visualization of the motion of a droplet of ferrofluid in water. With this TWMPI is the fastest MPI-system available and gives access to fundamental studies of particle dynamics. The presented Traveling Wave MPI-system is an alternative scanner concept, which sets itself apart from other MPI-scanners. Mouse-sized objects can be imaged in a dynamic way in very short times. The feasibility and performance of the TWMPI-concept were suc-cessfully demonstrated in various measurements considerably exceeding the original aims. KW - Magnetpartikelbildgebung KW - Traveling Wave Magnetic Particle Imaging KW - Traveling Wave Magnetic Particle Imaging KW - tomographic imaging method KW - molecular imaging KW - field free point (FFP) KW - Tomografie Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-132700 ER - TY - CHAP A1 - Werner, Rudolf A. A1 - Marcus, Charles A1 - Sheikhbahaei, Sara A1 - Higuchi, Takahiro A1 - Solnes, Lilja B. A1 - Rowe, Steven P. A1 - Buck, Andreas K. A1 - Lapa, Constantin A1 - Javadi, Mehrbod S. T1 - Diagnostic Accuracy of Visual Assessment of an Initial DaT-Scan in Comparison to a Fully Automatic Semiquantitative Method T2 - Journal of Nuclear Medicine N2 - No abstract available. KW - Parkinson-Krankheit KW - SPECT KW - Parkinson KW - Parkinson Disease KW - DaTscan KW - Ioflupane KW - molecular imaging Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-162208 UR - http://jnm.snmjournals.org/content/59/supplement_1/626.abstract SN - 0161-5505 N1 - This research was originally published in JNM. Rudolf A. Werner, Charles Marcus, Sara Sheikhbahaei, Takahiro Higuchi, Lilja B. Solnes, Steven P. Rowe, Andreas K. Buck, Constantin Lapa, Mehrbod S. Javadi. Diagnostic Accuracy of Visual Assessment of an Initial DaT-Scan in Comparison to a Fully Automatic Semiquantitative Method. J Nucl Med. May 1, 2018; vol. 59 no. supplement 1:626. © SNMMI. VL - 59 IS - Supplement No. 1 SP - 626 ER - TY - CHAP A1 - Werner, Rudolf A. A1 - Marcus, Charles A1 - Sheikhbahaei, Sara A1 - Higuchi, Takahiro A1 - Solnes, Lilja B. A1 - Rowe, Steven P. A1 - Buck, Andreas K. A1 - Lapa, Constantin A1 - Javadi, Mehrbod S. T1 - The Impact of Ageing on Dopamine Transporter Imaging T2 - Journal of Nuclear Medicine N2 - No abstract available. KW - Parkinson-Krankheit KW - Parkinson KW - Parkinson Disease KW - DaTscan KW - Ioflupane KW - SPECT KW - molecular imaging KW - ageing Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-162213 UR - http://jnm.snmjournals.org/content/59/supplement_1/1646.abstract SN - 0161-5505 N1 - This research was originally published in JNM. Rudolf A. Werner, Charles Marcus, Sara Sheikhbahaei, Takahiro Higuchi, Lilja B. Solnes, Steven P. Rowe, Andreas K. Buck, Constantin Lapa, Mehrbod S. Javadi. The Impact of Ageing on Dopamine Transporter Imaging. J Nucl Med. May 1, 2018; vol. 59 no. supplement 1:1646. © SNMMI. VL - 59 IS - Supplement No 1 SP - 1646 ER -